ArticleThe Journal of antimicrobial chemotherapy2025
Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time-kill experiments to a mouse pneumonia model.
Article in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- In vitro and in vivo synergistic effects of cyclizine and piroxicam in combination with linezolid against methicillin-resistant Staphylococcus aureus.Applied microbiology and biotechnology · 2026Article
- The COMBINE pneumonia model: a multicenter study to standardize a mouse pneumonia model withMicrobiology spectrum · 2026Article
- PBPK/PD Model of Vancomycin in Sepsis: Linking Interstitial Exposure in Perfusion-Limited Tissues to MRSA Infection.Pharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesMRSA is one of the main pathogens that cause nosocomial pneumonia. Based on longitudinal in vitro and in vivo data, a pharmacokinetic-pharmacodynamic (PKPD) model was built to quantify the effect of two control antibiotics (LZD and VAN) for Gram-positive bacteria in a standardized mouse pneumonia model.
methodsThe PKPD model was developed for data generated on the MRSA strain 160 079 in static in vitro time-kill experiments and thereafter adjusted to fit data from lungs of neutropenic mice administered with single or multiple doses of LZD (0.5-40 mg/kg) or VAN (1-40 mg/kg). Simulations with human PK were run to predict antibacterial response in patients.
resultsBacterial regrowth observed in vitro when exposed to VAN concentrations was described by an adaptive resistance model. The selected MRSA isolate showed good virulence in the mouse pneumonia model. Bacterial load in lungs decreased up to 2-log with respect to control mice after LZD and VAN treatment. A 70%-75% lower killing rate was estimated for the in vivo data when compared with in vitro. Simulations displayed bacterial stasis at 24 h for patients infected with bacteria with MICs below the clinical breakpoint for both drugs after administering standard-of-care dosing regimens.
conclusionsA translational workflow allowed us to build a PKPD model with both in vitro and in vivo data that characterized bacterial dynamics following LZD and VAN exposure, showing that this approach can inform the development of antibiotics. We also showcased the first successful use of the standardized mouse pneumonia model for Gram-positive bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.